



# Q218 RESULTS

**+2%**

**NET REVENUE\***

**\$4.1 BN**

GAAP NET REVENUE  
\$4.1BN

**+10%**

**PERFORMANCE  
NET INCOME  
PER SHARE\***

**\$4.42**

GAAP LOSS PER SHARE  
\$1.39

**ALLERGAN RAISED  
FULL-YEAR 2018 GUIDANCE  
FOR NON-GAAP NET  
REVENUE & NON-GAAP  
PERFORMANCE NET  
INCOME PER SHARE**

**POSITIVE RESULTS  
IN 7 TOPLINE STUDIES  
FROM 5 KEY PIPELINE  
PROGRAMS IN 1H2018**

ALLERGAN'S BOARD  
OF DIRECTORS AUTHORIZES  
**NEW \$2.0 BILLION SHARE  
REPURCHASE PROGRAM**

\*Growth percentages are versus Q2 2017.  
Please refer to the GAAP to non-GAAP tables in July 26, 2018 Press Release on Allergan.com for a reconciliation of our non-GAAP results.